The method remains in the development phase. There is insufficient scientific evidence for drawing conclusions about benefits for patients and the methods cost-effectiveness (Evidence grade 4). Results from randomized controlled trials are necessary to assess fully the positive and negative effects of the method and its cost-effectiveness.